(CLARI) Clariane SE - Ratings and Ratios
Nursing Homes, Assisted Living, Memory Care
CLARI EPS (Earnings per Share)
CLARI Revenue
Description: CLARI Clariane SE
Clariane SE is a French healthcare facilities company, operating in the health care facilities sub-industry as classified by GICS. The companys stock is listed as common stock under the ticker symbol CLARI.
To assess the investment potential of Clariane SE, key performance indicators (KPIs) such as revenue growth, EBITDA margin, and debt-to-equity ratio are crucial. The negative Return on Equity (RoE) of -2.43% indicates that the company is currently not generating profits for its shareholders, suggesting potential underlying issues that need to be addressed.
The forward Price-to-Earnings (P/E) ratio of 36.10 implies that investors are expecting future earnings growth, despite the current lack of profitability. This could be attributed to various factors, including potential restructuring efforts, new business opportunities, or anticipated improvements in the healthcare facilities market.
The healthcare facilities sector is influenced by key economic drivers such as demographic changes (e.g., aging population), government healthcare policies, and overall economic conditions. Clariane SEs performance is likely tied to these factors, and any significant changes could impact the companys financials and stock performance.
From a technical standpoint, the stocks last price is below its short-term moving averages (SMA20 and SMA50), indicating a potential short-term downtrend. However, the SMA200 is significantly lower, suggesting a longer-term uptrend. The Average True Range (ATR) indicates moderate volatility, and the beta of 0.876 suggests that the stocks price movements are relatively less volatile compared to the overall market.
CLARI Stock Overview
| Market Cap in USD | 1,832m |
| Sub-Industry | Health Care Facilities |
| IPO / Inception |
CLARI Stock Ratings
| Growth Rating | 4.82% |
| Fundamental | 56.3% |
| Dividend Rating | 1.0% |
| Return 12m vs S&P 500 | 95.2% |
| Analyst Rating | - |
CLARI Dividends
Currently no dividends paidCLARI Growth Ratios
| Growth Correlation 3m | -86.8% |
| Growth Correlation 12m | 90.2% |
| Growth Correlation 5y | -84.2% |
| CAGR 5y | -10.89% |
| CAGR/Max DD 3y | -0.12 |
| CAGR/Mean DD 3y | -0.24 |
| Sharpe Ratio 12m | 1.40 |
| Alpha | 0.08 |
| Beta | 0.938 |
| Volatility | 52.15% |
| Current Volume | 379.8k |
| Average Volume 20d | 433.5k |
| Stop Loss | 4 (-5.2%) |
| Signal | -1.02 |
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (-86.6m TTM) > 0 and > 6% of Revenue (6% = 476.0m TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA -0.65pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -12.22% (prev -11.76%; Δ -0.46pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 1.03b > Net Income -86.6m (YES >=105%, WARN >=100%) |
| Net Debt (7.46b) to EBITDA (789.6m) ratio: 9.45 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.67 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (356.8m) change vs 12m ago 145.1% (target <= -2.0% for YES) |
| Gross Margin 46.86% (prev 18.78%; Δ 28.08pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 53.62% (prev 49.70%; Δ 3.92pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.90 (EBITDA TTM 789.6m / Interest Expense TTM 336.4m) >= 6 (WARN >= 3) |
Altman Z'' 0.36
| (A) -0.07 = (Total Current Assets 1.94b - Total Current Liabilities 2.91b) / Total Assets 14.41b |
| (B) 0.14 = Retained Earnings (Balance) 2.07b / Total Assets 14.41b |
| (C) 0.02 = EBIT TTM 302.3m / Avg Total Assets 14.80b |
| (D) 0.19 = Book Value of Equity 2.07b / Total Liabilities 10.83b |
| Total Rating: 0.36 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 56.30
| 1. Piotroski 3.50pt = -1.50 |
| 2. FCF Yield 7.35% = 3.68 |
| 3. FCF Margin 4.43% = 1.11 |
| 4. Debt/Equity 0.92 = 2.09 |
| 5. Debt/Ebitda 4.20 = -2.50 |
| 6. ROIC - WACC (= 2.42)% = 3.03 |
| 7. RoE -2.43% = -0.41 |
| 8. Rev. Trend 43.04% = 3.23 |
| 9. EPS Trend -48.42% = -2.42 |
What is the price of CLARI shares?
Over the past week, the price has changed by -1.08%, over one month by -11.54%, over three months by -7.90% and over the past year by +133.17%.
Is Clariane SE a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CLARI is around 3.81 EUR . This means that CLARI is currently overvalued and has a potential downside of -9.72%.
Is CLARI a buy, sell or hold?
What are the forecasts/targets for the CLARI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 5.2 | 22.3% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 4.3 | 1.7% |
CLARI Fundamental Data Overview
Market Cap EUR = 1.55b (1.55b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 84.0m EUR (last quarter)
P/E Forward = 36.1011
P/S = 0.2921
P/B = 0.4239
Beta = 0.885
Revenue TTM = 7.93b EUR
EBIT TTM = 302.3m EUR
EBITDA TTM = 789.6m EUR
Long Term Debt = 3.31b EUR (from longTermDebt, last quarter)
Short Term Debt = 5.63m EUR (from shortTermDebt, last quarter)
Debt = 3.32b EUR (Calculated: Short Term 5.63m + Long Term 3.31b)
Net Debt = 7.46b EUR (from netDebt column, last fiscal year)
Enterprise Value = 4.78b EUR (1.55b + Debt 3.32b - CCE 84.0m)
Interest Coverage Ratio = 0.90 (Ebit TTM 302.3m / Interest Expense TTM 336.4m)
FCF Yield = 7.35% (FCF TTM 351.5m / Enterprise Value 4.78b)
FCF Margin = 4.43% (FCF TTM 351.5m / Revenue TTM 7.93b)
Net Margin = -1.09% (Net Income TTM -86.6m / Revenue TTM 7.93b)
Gross Margin = 46.86% ((Revenue TTM 7.93b - Cost of Revenue TTM 4.22b) / Revenue TTM)
Tobins Q-Ratio = 2.31 (Enterprise Value 4.78b / Book Value Of Equity 2.07b)
Interest Expense / Debt = 5.05% (Interest Expense 167.5m / Debt 3.32b)
Taxrate = unknown
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 0.67 (Total Current Assets 1.94b / Total Current Liabilities 2.91b)
Debt / Equity = 0.92 (Debt 3.32b / last Quarter total Stockholder Equity 3.59b)
Debt / EBITDA = 4.20 (Net Debt 7.46b / EBITDA 789.6m)
Debt / FCF = 9.43 (Debt 3.32b / FCF TTM 351.5m)
Total Stockholder Equity = 3.56b (last 4 quarters mean)
RoA = -0.60% (Net Income -86.6m, Total Assets 14.41b )
RoE = -2.43% (Net Income TTM -86.6m / Total Stockholder Equity 3.56b)
RoCE = 4.40% (Ebit 302.3m / (Equity 3.56b + L.T.Debt 3.31b))
RoIC = 2.42% (Ebit 302.3m / (Assets 14.41b - Current Assets 1.94b))
WACC = unknown (E(1.55b)/V(4.87b) * Re(9.47%)) + (D(3.32b)/V(4.87b) * Rd(5.05%) * (1-Tc(none)))
Shares Correlation 3-Years: 7.75 | Cagr: 5.58%
Discount Rate = 9.47% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 75.16% ; FCFE base≈398.5m ; Y1≈448.7m ; Y5≈603.4m
Fair Price DCF = 22.80 (DCF Value 8.13b / Shares Outstanding 356.5m; 5y FCF grow 14.61% → 3.0% )
EPS Correlation: -48.42 | EPS CAGR: -35.59% | SUE: 0.0 | # QB: 0
Revenue Correlation: 43.04 | Revenue CAGR: 45.59% | SUE: 1.75 | # QB: 1